Which care choice might ease my soreness?

What can I try at home first?

Choose movement that feels gentle enough to repeat, such as walking or simple strength work. You’re looking for comfort, not a test of toughness.

If the joint swells after activity, a wrapped cold pack may calm it. Warmth often feels better when stiffness is the main trouble.

Sturdy shoes and short breaks during heavy chores can spare a sore hip or knee. These changes won’t tell you what caused the soreness.

If several weeks pass without enough relief, an exam can find the part that hurts. You can then compare care with better information.

What does QC Kinetix offer without surgery?

QC Kinetix provides regenerative treatments, meaning office care that uses material from a blood draw or bone marrow and puts it at the sore joint. Treatment comes only after the exam.

To make platelet-rich plasma, called PRP, the clinic spins blood drawn from you and keeps the part containing more platelets for use during the office procedure at your visit. Concentrated PRP puts still more platelets into that material.

The clinic also calls these choices natural pain treatments because the material comes from your body. They may reduce soreness or make movement easier.

Joint preservation means keeping your own joint in use rather than moving at once to surgery. The phrase doesn’t say that worn cartilage grows back.

Before discussing a procedure, the medical provider examines the sore area and goes over your health. You can ask if a doctor, a nurse, or another trained clinic member will do that work.

People asking about knee or hip surgery alternatives may want more time before an operation. A consultation can explain what this care can and can’t promise.

When might surgery still make sense?

Surgery may be the sound choice when joint damage is severe and daily life has become difficult. It isn’t a defeat.

Biologic therapy can’t promise that you’ll avoid an operation your doctor advises. Please ask how each choice may affect walking, sleep, recovery, and cost.

Any treatment may fail to give enough relief, and a fair talk includes that chance. We’re here to make the choices easier to understand.

Sources

1. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

2. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. A meta-analysis and metaregression of 14 RCTs (978 patients) of dextrose prolotherapy for knee OA found favourable effects on pain, global function and quality of life versus placebo injection and non-invasive control, and effects COMPARABLE to other invasive therapies at each follow-up duration - with the authors cautioning that heterogeneity and risk of bias across the included trials require the results to be interpreted cautiously.

   Chen YW, et al. — Effectiveness, Compliance, and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials.. Clinical Rehabilitation, 2022. DOI: 10.1177/02692155221086213.

6. A multicenter single-blind RCT randomised 200 patients 1:1:1 to a single injection of saline, hyaluronic acid or amniotic suspension allograft. ASA produced significant KOOS and VAS improvements maintained through 12 months with a 63.2% OMERACT-OARSI responder rate, no radiographic differences, and no concerning immunoglobulin or anti-HLA responses. Adverse events with ASA were comparable to HA, while NO treatment-emergent adverse events were reported in the saline group.

   Gomoll AH, et al. — Safety and Efficacy of an Amniotic Suspension Allograft Injection Over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2021.02.044.

7. A 2026 systematic review of leukocyte-rich versus leukocyte-poor PRP for osteoarthritis concluded the current evidence is insufficient to determine whether adding leukocytes provides any clinical benefit, that results generally show no significant difference between the two, and that there is no conclusive evidence local reactions are caused by leukocytes specifically.

   Martin-Vega M, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.. Regenerative Therapy, 2026. DOI: 10.1016/j.reth.2026.101078.

8. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

9. The companion ESSKA-ORBIT consensus on cell-based therapy (77 experts, 22 countries, 27 statements) found only 5 of 27 statements reached recommendation level A or B; 22 were rated C or D. It concluded that cell-based therapy shows clinical benefit in pain and function up to 12 months for KL grades 1-3 with some benefit in selected KL 4, but that because of limited high-quality studies and NO clear superiority over other injectables it should be considered a SECOND-LINE option, after other non-operative treatment fails.

   de Girolamo L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.. Knee Surgery, Sports Traumatology, Arthroscopy, 2025. DOI: 10.1002/ksa.70001.